Non-Hodgkin Lymphoma in Adults

We use molecular and genetic tests to diagnose non-Hodgkin lymphoma. This form of cancer arises in the body’s lymphatic system—the network of vessels, nodes, and other organs that drain excess fluid from tissues and help the body fight infections. These tests enable our hematologists, or blood cancer specialists, to create a personalized treatment plan for you. Approaches may include chemotherapy, targeted medications, stem cell transplantation, and radiation therapy. We can also determine whether you may benefit from new therapies being studied in clinical trials.

Clinical Trials and Research Studies

Phase 1/2

AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

Phase 1/2

A Phase 1b Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine ( Rituximab) Gemcitabine Lenalidomide or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Phase 1

A Phase 1 Dose Escalation Study Of The Safety And Pharmacokinetics Of Lam-002A (Apilimod Dimesylate Capsules) Administered Orally In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin'S Lymphoma

Phase 1/2

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma